SYM FINANCIAL Corp Has $995,000 Holdings in Medtronic PLC (NYSE:MDT)

SYM FINANCIAL Corp grew its stake in Medtronic PLC (NYSE:MDT - Free Report) by 93.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,072 shares of the medical technology company's stock after acquiring an additional 5,353 shares during the quarter. SYM FINANCIAL Corp's holdings in Medtronic were worth $995,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Burkett Financial Services LLC increased its stake in Medtronic by 185.0% during the 1st quarter. Burkett Financial Services LLC now owns 285 shares of the medical technology company's stock worth $26,000 after purchasing an additional 185 shares in the last quarter. Columbia River Financial Group LLC bought a new position in shares of Medtronic during the 1st quarter worth approximately $28,000. Wood Tarver Financial Group LLC bought a new position in shares of Medtronic during the 4th quarter worth approximately $27,000. Hughes Financial Services LLC bought a new position in shares of Medtronic during the 1st quarter worth approximately $32,000. Finally, Optiver Holding B.V. bought a new position in shares of Medtronic during the 4th quarter worth approximately $31,000. 82.06% of the stock is owned by institutional investors.

Medtronic Price Performance

Medtronic stock traded up $0.59 during midday trading on Friday, reaching $92.91. The company's stock had a trading volume of 5,168,389 shares, compared to its average volume of 7,748,498. The business has a 50-day moving average price of $86.91 and a 200-day moving average price of $87.44. Medtronic PLC has a 52 week low of $78.32 and a 52 week high of $96.25. The stock has a market cap of $119.16 billion, a PE ratio of 25.66, a price-to-earnings-growth ratio of 2.39 and a beta of 0.80. The company has a current ratio of 1.85, a quick ratio of 1.42 and a debt-to-equity ratio of 0.53.

Medtronic (NYSE:MDT - Get Free Report) last announced its quarterly earnings results on Wednesday, May 21st. The medical technology company reported $1.62 EPS for the quarter, beating analysts' consensus estimates of $1.58 by $0.04. Medtronic had a return on equity of 14.54% and a net margin of 13.90%. The firm had revenue of $8.93 billion for the quarter, compared to analyst estimates of $8.81 billion. During the same period last year, the firm posted $1.46 earnings per share. The business's revenue for the quarter was up 3.9% on a year-over-year basis. On average, sell-side analysts predict that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 11th. Investors of record on Friday, June 27th were paid a $0.71 dividend. This is a positive change from Medtronic's previous quarterly dividend of $0.70. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.06%. The ex-dividend date of this dividend was Friday, June 27th. Medtronic's payout ratio is currently 78.45%.

Analyst Upgrades and Downgrades

MDT has been the subject of several recent analyst reports. Wall Street Zen raised Medtronic from a "hold" rating to a "buy" rating in a report on Saturday, June 21st. Royal Bank Of Canada cut their price objective on Medtronic from $105.00 to $101.00 and set an "outperform" rating for the company in a report on Thursday, May 22nd. Mizuho increased their price objective on Medtronic from $98.00 to $100.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. Needham & Company LLC reaffirmed a "hold" rating on shares of Medtronic in a report on Friday, June 6th. Finally, William Blair raised Medtronic to a "hold" rating in a report on Friday, July 11th. Eleven analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $98.19.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.